Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?

被引:14
|
作者
Tselios, Konstantinos [1 ]
Gladman, Dafna D. [1 ]
Su, Jiandong [1 ]
Urowitz, Murray B. [1 ]
机构
[1] Univ Hlth Network, Toronto Lupus Clin, Ctr Prognosis Studies Rheumat Dis, Toronto, ON, Canada
关键词
LUPUS NEPHRITIS; ADVANCED KIDNEY DISEASE; PROGRESSION; STAGE RENAL-DISEASE; MYCOPHENOLATE-MOFETIL; INTRAVENOUS CYCLOPHOSPHAMIDE; PROGRESSION; RISK; CLASSIFICATION; HYPERTENSION; PREDICTORS; OUTCOMES; INDEX;
D O I
10.3899/jrheum.191064
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Advanced chronic kidney disease (CKD) carries an increased risk for progression to endstage renal disease (ESRD). We aimed to determine the rate of progression and the factors that drive the decline of renal function in lupus nephritis (LN). Methods. Patients with advanced LN-related CKD were identified from our longterm longitudinal cohort. Advanced CKD was defined as stage 3b [estimated glomerular filtration rate (eGFR) = 30-44 ml/min/1.73 m(2)] and stage 4 (eGFR = 15-29 ml/min/1.73 m(2)). All individuals were followed until progression to ESRD or the last visit and were divided into "progressors" and "non-progressors." Demographic, clinical, immunological, and therapeutic variables were compared at baseline. Multivariable Cox regression analysis (both time-dependent and independent) was performed to identify predictors for progression. Results. One hundred eighteen patients (74 CKD 3b and 44 CKD 4) were included. Forty-five patients progressed (29 to ESRD and 16 from CKD 3b to CKD 4) after 6 years on average. No significant decline in the renal function was observed in 73 patients ("non-progressors") after 10 years on average. Active serology (high anti-dsDNA titers and low complements C3/C4) at the time of CKD diagnosis and any increase of the daily prednisone dose after baseline were strongly associated with progression. Treatment with renin angiotensin system (RAS) blockers was associated with less risk for progression. Conclusion. Dialysis is not inevitable in LN-related advanced CKD because 62% of our patients did not progress over 10 years of followup on average. Certain predictors were identified to affect progression to ESRD.
引用
收藏
页码:1366 / 1373
页数:8
相关论文
共 50 条
  • [21] Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis A Case Series
    Snyder, Matthew S.
    Chen, Angel
    Furie, Richard
    Narain, Sonali
    Marder, Galina S.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2024, 30 (01) : 36 - 39
  • [22] Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease
    Wu, P-C
    Wu, C-J
    Lin, C-J
    Pan, C-F
    Chen, C-Y
    Huang, T-M
    Wu, C-H
    Lin, S-L
    Chen, Y-M
    Chen, L.
    Wu, V-C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (04) : 442 - 449
  • [23] Laxative use in patients with advanced chronic kidney disease transitioning to dialysis
    Sumida, Keiichi
    Dashputre, Ankur A.
    Potukuchi, Praveen K.
    Thomas, Fridtjof
    Obi, Yoshitsugu
    Molnar, Miklos Z.
    Gatwood, Justin D.
    Streja, Elani
    Kalantar-Zadeh, Kamyar
    Kovesdy, Csaba P.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (11) : 2018 - 2026
  • [24] PENTOXIFYLLINE DECREASES DIALYSIS RISK IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE
    Wu, Pei-Chen
    Wu, Chih-Jen
    Wu, Vin-Cent
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [25] Dietary Protein Intake in Patients with Advanced Chronic Kidney Disease and on Dialysis
    Dukkipati, Ramanath
    Noori, Nazanin
    Feroze, Usama
    Kopple, Joel D.
    SEMINARS IN DIALYSIS, 2010, 23 (04) : 365 - 372
  • [26] IMPACT OF TIME TO REMISSION, FLARES AND EXPOSURE TO IMMUNOSUPPRESSIVES ON THE DEVELOPMENT OF ADVANCED CHRONIC KIDNEY DISEASE (STAGE IV OR WORSE) IN LUPUS NEPHRITIS
    Tselios, K.
    Gladman, D. D.
    Su, J.
    Urowitz, M. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 654 - 655
  • [27] Transcriptomic and Epigenetic Alterations in Dendritic Cells Correspond With Chronic Kidney Disease in Lupus Nephritis
    Wardowska, Anna
    Komorniczak, Michal
    Bullo-Piontecka, Barbara
    Debska-Slizien, M. Alicja
    Pikula, Michal
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [28] REVERSIBILITY OF LUPUS NEPHRITIS IN DIALYSIS
    JI, YL
    YE, RG
    LI, HO
    KIDNEY INTERNATIONAL, 1992, 42 (02) : 501 - 501
  • [29] Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
    Gladman, Dafna
    Tselios, Konstantinos
    Su, Jiandong
    Urowitz, Murray
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4063 - 4065
  • [30] Renal flare as a biomarker of incident and progressive chronic kidney disease in patients with lupus nephritis
    Parikh, S.
    McKinley, A.
    Rovin, B. H.
    ARTHRITIS RESEARCH & THERAPY, 2012, 14